A Systematic Review: Evaluasi Terhadap Kejadian Perdarahan Pada Pasien ACS dengan Terapi Antiplatelet Tunggal Dibandingkan Terapi Antiplatelet Ganda Pasca Percutaneous Coronary Intervention (PCI)

Allysia Maria Vianney Putri; Rini Noviyani

doi:10.57213/jrikuf.v3i3.785

Authors

Allysia Maria Vianney Putri Universitas Udayana
Rini Noviyani Universitas Udayana

DOI:

https://doi.org/10.57213/jrikuf.v3i3.785

Keywords:

Acute coronary syndrome (ACS), Antiplatelet, Bleeding times, Literature review, Percutaneous coronary intervention (PCI)

Abstract

Acute Coronary Syndrome (ACS) is a cardiovascular disorder with a high global mortality rate, including in Indonesia. Antiplatelet therapy administered either as monotherapy or as Dual Antiplatelet Therapy (DAPT) plays a crucial role in managing ACS patients after Percutaneous Coronary Intervention (PCI). However, such therapies carry a bleeding risk that requires careful evaluation. Previous studies on the pharmacological use of antiplatelet agents in post-PCI ACS patients have shown varying results. Therefore, this systematic review aims to compare the incidence of bleeding between single and dual antiplatelet therapies in ACS patients following PCI. Literature was retrieved from PubMed and Google Scholar using relevant keywords, resulting in 11 articles that met the inclusion criteria for further analysis. The reviewed studies include meta-analyses, randomized controlled trials (RCT), and cohort studies. Findings indicate that P2Y12 inhibitor monotherapy following short-term DAPT significantly reduces bleeding risk without increasing ischemic events, particularly in high-risk patients. This treatment strategy demonstrates better safety and comparable efficacy when compared to prolonged DAPT. This review is expected to serve as a reference for selecting safer and more appropriate antiplatelet therapy for ACS patients post-PCI, and as a foundation for future clinical policy development.

References

Alagna, G., Trimarchi, G., Cascone, A., Villari, A., Cavolina, G., Campanella, F., et al. (2025). Effectiveness and safety of ticagrelor monotherapy after short-duration dual antiplatelet therapy in PCI patients: A systematic review and meta-analysis. The American Journal of Cardiology, 241, 69–74.

Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., & Chieffo, A. (2023). ESC Guidelines for the Management of Acute Coronary Syndromes. European Heart Journal, 44, 3720–3826.

Dawson, A. A., Forman, D. E., Wang, T. Y., Chikwe, J., Kunadian, V., Rich, M. W., et al. (2021). Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association. Circulation, 147, 32–62.

Gimbel, M., Qaderdan, K., Willemsen, L., Hermanides, R., Bergmeijer, T., Vrey, E. D., et al. (2020). Clopidogrel Versus Ticagrelor or Prasugrel in Patients Aged 70 Years or Older with Non-ST-Elevation Acute Coronary Syndrome (Popular AGE): The Randomised, Open-Label, Non-Inferiority Trial. The Lancet, 395, 1374–1381.

Gragnano, F., Mehran, R., Branca, M., Franzone, A., Baber, U., Jang, Y., et al. (2023). P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. Journal of the American College of Cardiology, 81(6), 537–552.

Hahn, J. Y., Song, Y. B., Oh, J. H., Chun, W. J., Park, Y. H., Jang, W. J., et al. (2019). Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA, 321(24), 2428–2437.

IHME. (2024). Global Burden of Disease in Indonesia 2021. https://vizhub.healthdata.org/gbd-compare/#

Juzar, D. A., Muzakkir, A. F., Ilhami, Y. R., Taufiq, N., Astiawati, T., RA, I. M. J., et al. (2022). Management of Acute Coronary Syndrome Indonesia: Insight from One ACS Multicenter Registry. Indonesian Journal of Cardiology, 43(2), 45–55.

Karunarathna, I., Jayawardana, A., & Bandara, S. (2024). Antiplatelet Therapy: Mechanisms, Indications, Administration Mechanisms, Indications, and Administration. New Delhi, India.

Kemenkes RI. (2019). Keputusan Menteri Kesehatan Republik Indonesia, Nomor HK.01.07/MENKES/675/2019, tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sindroma Koroner Akut [Decree of the Minister of Health of the Republic of Indonesia, Number HK.01.07/MENKES/675/2019, concerning the National Guidelines for Medical Services for the Management of Acute Coronary Syndrome]. Kementrian Kesehatan Republik Indonesia.

Kemenkes RI. (2021). Profil Kesehatan Indonesia [Indonesian Health Profile]. Kementrian Kesehatan Republik Indonesia.

Malik, A. H., Yandrapalli, S., Shetty, S. S., Aronow, W. S., Cooper, H. A., & Panza, J. A. (2020). Meta-analysis of dual antiplatelet therapy versus monotherapy with P2Y12 inhibitors in patients after percutaneous coronary intervention. The American Journal of Cardiology, 127, 25–29.

Mehran, R., Nikolsky, E., Lansky, A. J., Kirtane, A. J., Young-Hak, K., Feit, F., et al. (2011). Impact of Chronic Kidney Disease on Early (30-Day) and Late (1 Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy. Journal of the American College of Cardiology: Cardiovascular Interventions, 2, 748–757.

Mensah, G. A., Habtegiorgis Abate, Y., Abbasian, M., Abd-Allah, F., Abdollahi, A., Abdollahi, M., et al. (2023). Global Burden of Cardiovascular Diseases and Risks, 1990-2022. Journal of the American College of Cardiology, 82(25), 2350–2473.

Michael, & Ramadhania, Z. M. (2017). Obat Penginduksi Perdarahan [Bleeding-Inducing Drugs]. Farmaka, 15(4), 33–39.

Moisi, M. I., Vesa, C. M., Roșan, L., Țica, O., Zaha, C. D., Ardelean, A., et al. (2021). Morbidity and Mortality in Patients with Acute Coronary Syndrome with and without Chronic Kidney Disease and Physicans Atitude Regarding Theraphy in the Two Groups. Iranian Journal of Public Health, 50, 1726–1728.

Nalfriadi, M., Verdoia, M., Laera, N., Cao, D., & De Luca, G. (2018). New Insights into Pathophysiology and New Risk Factors for ACS. Journal of Clinical Medicine, 12, 2883–2909.

Nardin, M., Verdoia, M., Laera, N., Cao, D., & De Luca, G. (2023). New Insights into Pathophysiology and New Risk Factors for ACS. Journal of Clinical Medicine, 12, 2883–2909.

Park, D. W., Kwon, O., Jang, J. S., Yun, S. C., Park, H., Kang, D. Y., et al. (2019). Clinically Significant Bleeding with Ticagrelor Versus Clopidogrel in Korean Patients with Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial. Circulation, 140(23), 1865–1877.

Pernias, V., Garcia Acuna, J. M., Raposeiras-Roubin, S., Barrabes, J. A., Cordero, A., Martinez-Selles, M., et al. (2021). Impact of Comorbidities in The Decision of Using Invasive Management in Elderly Patients with NSTEACS. REC:Interventional Cardiology, 3, 15–20.

Pham, P. A., Pham, P. T., Pham, P. C., Miller, J. M., Pham, P. M., & Pham, S. V. (2011). Implications of Bleeding in Acute Coronary Syndrome and Percutaneous Coronary Intervention. Vascular Health and Risk Management, 7, 551–567.

Roh, J. W., Hahn, J. Y., Oh, J. H., Chun, W. J., Park, Y. H., Jang, W. J., et al. (2021). P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial. Cardiology Journal, 28(6), 855–863.

Serruys, P. W., Takahashi, K., Chichareon, P., Kogame, N., Tomaniak, M., Modolo, R., et al. (2019). Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European Heart Journal, 453, 1–11.

Shin, E. S., Her, A. Y., Kim, B., Hahn, J. Y., Song, Y. B., Lee, J. M., et al. (2023). Sex-based outcomes of P2Y12 inhibitor monotherapy after three months of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention. Journal of Korean Medical Science, 38(45), 383.

Song, P. S., Park, Y. H., Oh, J. H., Song, Y. B., Choi, S. H., Gwon, H. C., et al. (2021). P2Y12 inhibitor monotherapy versus conventional dual antiplatelet therapy or aspirin monotherapy in acute coronary syndrome: A pooled analysis of the SMART-DATE and SMART-CHOICE Trials. The American Journal of Cardiology, 150, 47–54.

Steg, P. G., Huber, K., Andreotti, F., Arnesen, H., Atar, D., Badimon, L., et al. (2011). Bleeding in Acute Coronary Syndromes and Percutaneous Coronary Interventions: Position Paper by The Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal, 32, 1854–1864.

Storey, R. F., Angiolillo, D. J., Patil, S. B., Desai, B., Ecob, R., Husted, S., et al. (2010). Inhibitory Effects of Ticagrelor Compared with Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes: The PLATO (Platelet Inhibition and Patient Outcomes) PLATELET Substudy. Journal of the American College of Cardiology, 56(18), 1456–1462.

Szummer, K., Montez-Rath, M. E., Alfredsson, J., Erlinge, D., Lindahl, B., Hofmann, R., et al. (2020). Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. Circulation, 142(18), 1700–1708.

Tan, E. X., Baibhav, B., Thakkar, S., Azhar, A. Z., & Rao, M. (2022). Clopidogrel versus aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysis. Current Problems in Cardiology, 47(3), 101174.

Tersalvi, G., Biasco, L., Cioffi, G. M., & Pedrazzini, G. (2020). Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective. Journal of Clinical Medicine, 9, 2064–2083.

Valgimigli, M., Franchin, L., Varbella, F., Calabró, P., Andò, G., Limbruno, U., et al. (2021). Ticagrelor Monotherapy Versus Dual Antiplatelet Therapy After PCI: An Individual Patient Data Pairwise and Network Meta-Analysis. Circulation, 143(7), 621–631.

Vranckx, P., Valgimigli, M., Jüni, P., Hamm, C., Steg, P. G., Heg, D., et al. (2018). Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs standard dual antiplatelet therapy after drug-eluting stent implantation: the GLOBAL LEADERS trial. The Lancet, 392(10151), 940–949.

Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., et al. (2009). Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 361(11), 1045–1057.

Waterbury, T. M., Tarantini, G., Vogel, B., Mehran, R., Gersh, B. J., & Gulati, R. (2020). Non-atherosclerotic Causes of Acute Coronary Syndromes. Nature Reviews Cardiology, 17, 229–241.

Yuan, D., Chu, J., Qian, J., Lin, H., Zhu, G., Chen, F., et al. (2023). New Concepts on the Pathophysiology of Acute Coronary Syndrome. Reviews in Cardiovascular Medicine, 24, 112–122.